Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

As A New Rival Approaches, PARP Makers Look To Carve Out Their Niche

Executive Summary

The US FDA has granted priority review for Pfizer's talazoparib, which would be the fourth PARP inhibitor on the market, though only the second for breast cancer behind Lynparza. Pfizer has a long-term eye on a combination of talazoparib with its PD-L1 inhibitor Bavencio, Oncology CMO Rothenberg told Scrip at ASCO. 

You may also be interested in...



Pfizer Expands In Breast Cancer With Talazoparib Approval

The PARP inhibitor, acquired with Medivation, will launch in a field where Pfizer already has commercial experience through its CDK4/6 inhibitor Ibrance. 

Finance Watch: Ascletis First Biotech To List Under New Hong Kong Rules, BeiGene Joins In

Ascletis was the first with a new listing under new Hong Kong rules, but BeiGene also sold shares on the HKEX; the companies raised more than $1bn combined. Also, TherapeuticsMD sold stock in the US to commercialize Imvexxy, Curon raised the latest $150m VC mega-round, and NewLink cut jobs in R&D refocus.

AstraZeneca Looks To Deliver On Its Promises In Oncology

Global Head of Oncology Dave Fredrickson took over the commercial leadership role in October. Now he is overseeing several key growth drivers, including Imfinizi and Lynparza, while building out a new hematology franchise. Fredrickson talked with Scrip about AstraZeneca's oncology strategy at ASCO. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1128165

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel